Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus

NCT01835730 is registered in ClinicalTrials.gov with PhaseBio Pharmaceuticals Inc. as lead sponsor.

NCT NCT01835730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01835730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2013
Completion date
May 31, 2014
Enrollment
37 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus (t2dm)